1. Home
  2. ETNB vs AMAL Comparison

ETNB vs AMAL Comparison

Compare ETNB & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • AMAL
  • Stock Information
  • Founded
  • ETNB 2018
  • AMAL 1923
  • Country
  • ETNB United States
  • AMAL United States
  • Employees
  • ETNB N/A
  • AMAL N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • AMAL Commercial Banks
  • Sector
  • ETNB Health Care
  • AMAL Finance
  • Exchange
  • ETNB Nasdaq
  • AMAL Nasdaq
  • Market Cap
  • ETNB 1.0B
  • AMAL 867.2M
  • IPO Year
  • ETNB 2019
  • AMAL 2018
  • Fundamental
  • Price
  • ETNB $10.05
  • AMAL $29.86
  • Analyst Decision
  • ETNB Strong Buy
  • AMAL Buy
  • Analyst Count
  • ETNB 8
  • AMAL 3
  • Target Price
  • ETNB $26.43
  • AMAL $36.50
  • AVG Volume (30 Days)
  • ETNB 2.1M
  • AMAL 161.7K
  • Earning Date
  • ETNB 05-01-2025
  • AMAL 07-24-2025
  • Dividend Yield
  • ETNB N/A
  • AMAL 1.85%
  • EPS Growth
  • ETNB N/A
  • AMAL 9.81
  • EPS
  • ETNB N/A
  • AMAL 3.36
  • Revenue
  • ETNB N/A
  • AMAL $303,970,000.00
  • Revenue This Year
  • ETNB N/A
  • AMAL $11.72
  • Revenue Next Year
  • ETNB N/A
  • AMAL $12.48
  • P/E Ratio
  • ETNB N/A
  • AMAL $8.99
  • Revenue Growth
  • ETNB N/A
  • AMAL 7.13
  • 52 Week Low
  • ETNB $4.16
  • AMAL $24.02
  • 52 Week High
  • ETNB $11.84
  • AMAL $38.19
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 68.44
  • AMAL 49.34
  • Support Level
  • ETNB $8.94
  • AMAL $29.68
  • Resistance Level
  • ETNB $9.70
  • AMAL $30.90
  • Average True Range (ATR)
  • ETNB 0.73
  • AMAL 0.84
  • MACD
  • ETNB 0.14
  • AMAL -0.14
  • Stochastic Oscillator
  • ETNB 93.78
  • AMAL 26.75

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.

Share on Social Networks: